Hepatitis Forums
Fatty Liver Disease Main Forums => Nonalcoholic Steatohepatitis (NASH) => Topic started by: Hep Editors on April 17, 2019, 10:39:33 am
-
Gilead Sciences’ experimental non-alcoholic steatohepatitis (NASH) treatment selonsertib failed to reach its predefined one-year marker of success.
The Phase III STELLAR-4 study is a randomized, double-blind placebo-controlled trial evaluating the safety and efficacy of selonsertib in people with compensated cirrhosis (also known as severe, or F4, fibrosis) of the liver as a result of NASH. The study was open to participants between ages 18 and 70 years old.
Read more...
https://www.hepmag.com/article/gileads-nash-treatment-posts-disappointing-results